导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.40% | 2097/4773 |
| 近一周 | -1.52% | 492/5462 |
| 近一月 | -1.32% | 912/5421 |
| 近一季 | -4.55% | 1659/5209 |
| 近半年 | -10.22% | 3617/4920 |
| 近一年 | 3.48% | 1924/4366 |
| 近两年 | 28.11% | 2355/2954 |
| 近三年 | 18.74% | 1519/2253 |
| 成立以来 | 83.27% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.25% 770/4961 |
1.38% 3034/5312 |
- - |
- - |
| 2025 | 6.34% 2967/4813 |
-4.40% 3173/3635 |
0.98% 2512/4076 |
6.88% 3495/4524 |
3.06% 762/4813 |
| 2024 | 18.46% 600/3463 |
9.15% 143/2808 |
1.82% 442/3014 |
7.04% 2826/3129 |
-0.42% 1421/3463 |
| 2023 | 6.97% 156/2656 |
15.69% 208/2280 |
1.24% 228/2385 |
-3.34% 901/2515 |
-5.51% 1379/2655 |
| 2022 | -12.74% 297/2207 |
-10.63% 406/1919 |
2.34% 1310/2016 |
-9.45% 279/2113 |
5.36% 469/2208 |
| 2021 | 24.29% 123/1822 |
2.35% 221/1255 |
3.48% 970/1330 |
17.19% 66/1466 |
0.15% 1166/1822 |
| 2020 | 11.11% 831/1250 |
-7.27% 535/1028 |
0.69% 999/1067 |
8.72% 700/1164 |
9.45% 640/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博时央创ETF联接C VS. 长安沪深300非周期A(740101) |